NEWS

MOST RECENT POST
1 June 2015
Actavis Completes Acquisition of Auden Mckenzie

Actavis plc (NYSE: ACT) today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK. Actavis acquired Auden Mckenzie for approximately £306 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products. 


21 November 2014
Plenachol® 20 000 IU Capsules & Plenachol® 40 000 IU Capsules

MHRA grants Auden Mckenzie Ltd. Marketing Authorisations (licences) for the
Medicinal products Plenachol® 20 000 IU Capsules (PL 17507/0226) & Plenachol® 40 000 IU Capsules (PL 17507/0227).





16 July 2014
Clonazepam Auden

At the request of the Regulatory Authorities in the UK, Auden Mckenzie (Pharma Division) Ltd. have changed the name of Clonazepam Tablets to Clonazepam Auden (as we are the license holder) to ensure that epileptic patients are stabilised on a particular License Holder’s product. We can confirm that only the name has been changed on the packaging and that there has been no change in the formulation, manufacturing process or the quality of the product.





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17